Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Gastrointestinal Medicine
Volume 2013, Article ID 934875, 4 pages
Case Report

Anorectal Gastrointestinal Stromal Tumor: A Case Report and Literature Review

1Department of Surgery, Northern Railway Central Hospital, New Delhi, India
2Department of Radiology, ESI Model Hospital and PGIMSR, Basaidarapur, New Delhi 110001, India
3Department of Radiology, Northern Railway Central Hospital, New Delhi, India
4Department of Anaesthesia, Northern Railway Central Hospital, New Delhi, India

Received 29 January 2013; Accepted 25 February 2013

Academic Editors: G. Bassotti, O. I. Giouleme, and Ö. Yönem

Copyright © 2013 Sanjeev Singhal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Gastrointestinal stromal tumors or “GIST” are mesenchymal neoplasms expressing KIT(CD117) tyrosine kinase and showing the presence of activating mutations in KIT or PDGFRα (platelet-derived growth factor alpha). GIST of anal canal is an extremely rare tumor, accounting for only 3% of all anorectal mesenchymal tumors and 0.1–0.4% of all GIST. GIST with large tumor size and high mitotic activity are highly malignant, but the biological behavior of anorectal GIST is less clear. Abdominoperineal resection (APR) or conservative surgery is the best treatment option. Imatinib mesylate, a tyrosine kinase inhibitor, has shown promising results in its management. We present a case of anorectal GIST diagnosed by computed tomography (CT) scan, magnetic resonance imaging (MRI), and colonoscopy with biopsy. The patient underwent abdominoperineal resection (APR) and was confirmed on histopathology to have anal canal GIST with tumor size more than 5 cm in maximum dimension and mitotic figures more than 5/50 high power field (HPF). The CD117—immunoreactive score—was 3+ in spindled cells. Therefore the patient was put on adjuvant imatinib mesylate 400 mg daily.